Babcock & Wilcox (NYSE:BW) 주식

Babcock & Wilcox

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

PRGS

CNN 머니의 공포·탐욕 지수는 전체 시장 심리가 하락했음을 보여 주었다. 지수는 금요일에 &#34;극단적 공포&#34; 영역으로 이동했다.미국 증시는 지난 금요일(28일)에 하락세로 마감했으며, 다우존스 지수는 투자자들이 최근 관세 관련 뉴스를 평가하는 동안 세션 중 700포인트 이상 하락했다.

관세 우려 지속, 다우 지수 700p 하락: 투자심리 약화, 탐욕 지수는 &#39;극단적 공포&#39; 영역으로 이동

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

LOAR

월요일(31일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. PVH, 프로그레스 소프트웨어, 엑소스, 로어 홀딩스 및 밥콕 앤 윌콕스

월요일 주목해야 할 주식: PVH, 프로그레스 소프트웨어, 엑소스, 로어 홀딩스 및 밥콕 앤 윌콕스

Babcock & Wilcox Enterprises, Inc. Common Stock

Babcock & Wilcox Enterprises Inc

BorgWarner Inc

Better World Acquisition Corp Ordinary Shares

Better World Acquisition Corp Units (1 Ord & 1 War)

Better World Acquisition Corp Warrants (27/10/2025)

Bawag Group AG

Blue World Acquisition Corp

BLUE WORLD ACQUISITION CORP USD RTS

Blue World Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

Blue World Acquisition Corp Warrants (10/01/2029)

Betawave Corp

BrainsWay Ltd. - American Depositary Shares

BrainsWay Ltd

Bridgewater Bancshares, Inc. - Common Stock

Bridgewater Bancshares Inc

Bridgewater Bancshares, Inc. - Depositary Shares, Each Representing a 1/100th Interest in a Share of 5.875% Non-Cumulative Perpetual Preferred Stock, Series A

BOWEN COKING COAL LTD NEW by BOWEN COKING COAL LTD.

Bowen Coking Coal Ltd

BOWEN COKING COAL LTD by BOWEN COKING COAL LTD.

Blackwolf Copper and Gold Ltd

Bitwise Funds Trust Bitwise Web3 ETF

BW Energy Ltd

Boswell (JG) Co

Broadwind Inc

Amplify Commodity Trust Breakwave Tanker Shipping ETF

Bankwell Financial Group, Inc. - Common Stock

Bankwell Financial Group Inc

BrandywineGLOBAL Global Income Opportunities Fund Inc.

BrandywineGLOBAL - Global Income Opportunities Fund Inc

The Baldwin Insurance Group, Inc. - Class A Common Stock

The Baldwin Insurance Group Inc

BOARDWALKTECH SOFTWARE CP by Boardwalktech Software Corporation

Boardwalktech Software Corp

BW LPG Ltd

BW LPG Ltd ADR

Bowleven PLC

BROWNIE'S MARINE GRP INC by Brownie's Marine Group, Inc.

Brownie's Marine Group Inc

Bowman Consulting Group Ltd. - Common Stock

Bowman Consulting Group Ltd

BLACKROCK WRLD MNG TR by BlackRock World Mining Trust plc

Betterware de Mexico, S.A.P.I. de C.V. Ordinary Shares

Betterware de Mexico SAPI de CV

BORROWMONEY.COM INC by BorrowMoney.com inc.

BorrowMoney.com Inc

Verity Resources Ltd

Babcock & Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026

BAWANG INTL GRP HLDG LTD by Bawang Intl Group Holding Ltd.

BW Offshore Ltd

WOWJOINT HLDGS LTD by Wowjoint Holdings Limited

Wowjoint Holdings Ltd

Baader Bank Aktiengesellschaft

BLUE WATER PETROLEUM CP by Blue Water Petroleum Corp.

Blue Water Petroleum Corp

BALWIN PROPERTIES LTD by Balwin Properties Ltd.

Balwin Properties Ltd

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

ETF Opportunities Trust Brendan Wood TopGun Index ETF

BOWLIN TRAVEL CENTERS INC by Bowlin Travel Centers, Inc.

Bowlin Travel Centers Inc

Bakken Water Transfer Services Inc

BLUE WATER VENTURES INC by Blue Water Ventures International, Inc.

Blue Water Ventures International Inc

SPDR Bloomberg International Treasury Bond ETF

BWX Technologies Inc

BWX LIMITED ORD by BWX Limited

SPDR Bloomberg Short Term International Treasury Bond ETF

Babcock & Wilcox Enterprises, Inc. 7.75% Series A Cumulative Perpetual Preferred Stock

Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) shares are trading lower in Friday&#8217;s premarket session after the company reported its <a href="https://www.benzinga.com/pressreleases/25/04/n44757548/bny-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">first-quarter 2025 results</a>.
The firm reported first-quarter adjusted earnings per share of $1.58 (+26% YoY), beating the street view of $1.51.
Quarterly revenue of $4.972 billion, an increase of 6% year-over-year, surpassed the analyst consensus of $4.771 billion.
Fee revenue in the quarter grew 3% YoY to $3.403 billion. Net interest income rose 11% YoY, mainly due to reinvesting maturing securities at higher yields, though partially offset by shifts in the deposit mix.
Noninterest expense grew 2%, driven mainly by increased investments and employee merit raises, partially offset by efficiency-related cost savings.
Related: <a href="https://www.benzinga.com/25/04/44755949/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2" target="_blank" rel="noreferrer noopener">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
The provision for credit losses totaled $18 million for the quarter, reflecting increased reserves related to commercial real estate exposure.
The average deposits totaled $283 billion, up 1% year over year but down 1% from the prior quarter. The Tier 1 leverage ratio rose 35 basis points yearly to 6.2%.
Assets under custody and/or administration increased by 9% due to client inflows and market gains. Assets under management were flat, with market gains offset by net outflows.
BNY returned $1.1 billion to common shareholders year-to-date, including $343 million in dividends and $746 million in share repurchases, resulting in a total payout ratio of 95%.
As of March 31, BNY CET1 capital stood at $19.5 billion and Tier 1 capital at $24.8 billion, rising from December 31, 2024. The increases were driven by earnings and higher accumulated other comprehensive income, partially offset by capital returned via dividends and share repurchases.
&#8220;Looking ahead, we are prepared for a wide range of macroeconomic and market scenarios as the outlook for the operating environment is becoming more uncertain. Our work to operate BNY as a more platforms-oriented company, combined with our highly capitalized, liquid and lower credit risk balance sheet, positions us to manage dynamically and act as a source of strength as we support our clients in navigating the current environment,&#8221; BNY Mellon CEO Robin Vince said.
Dividend: BNY <a href="https://www.benzinga.com/pressreleases/25/04/n44757619/bny-declares-dividends" target="_blank" rel="noreferrer noopener">declared</a> a common stock dividend of 47 cents per share, payable on May 2, to shareholders of record as of the close of business on April 21.
Price Action: BK shares are trading lower by 1.16% to $75.72 premarket at the last check Friday.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44614042/jpmorgan-wells-fargo-morgan-stanley-bny-mellon-will-strike-a-cautious-tone-analysts" target="_blank" rel="noreferrer noopener">JPMorgan, Wells Fargo, Morgan Stanley, BNY Mellon Will &#8216;Strike A Cautious Tone&#8217;: Analysts</a></li>
</ul>
Image: Shutterstock

BNY Reports Strong Q1 Earnings, Still Sees Trouble Ahead In Uncertain Economy

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and lowers the price target from $78 to $75.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $75

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and lowers the price target from $120 to $113.

Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $113

Truist Securities analyst David Macdonald maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Buy and raises the price target from $610 to $660.

Truist Securities Maintains Buy on UnitedHealth Group, Raises Price Target to $660

<a href="https://finance.yahoo.com/live/" title="https://finance.yahoo.com/live/">https://finance.yahoo.com/live/</a>

Macro Economic Events

Economics

Federal Reserve

Fed's President Collins Says At This Point Expectation Is Fed Will Need To Hold Steady For Longer

STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) disclosed further elements of its program to reshape its global manufacturing footprint. This program builds on the one the company announced in October 2024 to <a href="https://www.benzinga.com/media/25/01/43399736/apple-and-tesla-supplier-stmicroelectronics-plans-up-to-3000-job-cuts-in-italy-and-france" target="_blank" rel="noreferrer noopener">strengthen its competitiveness</a>.
CEO Jean-Marc Chéry said the technology R&amp;D, design, and high-volume manufacturing activities in Italy and France will remain central to <a href="https://newsroom.st.com/media-center/press-item.html/c3330.html" target="_blank" rel="noreferrer noopener">its global operations</a>.
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) supplier STMicroelectronics&#8217; manufacturing operations aim to prioritize planned investments in future-ready infrastructure, such as 300mm silicon and 200mm silicon carbide wafer fabs.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44581377/stmicroelectronics-and-innoscience-partner-to-advance-gan-power-technology" rel="noreferrer noopener">STMicroelectronics And Innoscience Partner To Advance GaN Power Technology</a>
STMicroelectronics plans to continue investing in upgrading the technology used across its operations, deploying additional AI and automation to improve efficiency in technology R&amp;D and manufacturing.
Over the next three years, the reshaping of STMicroelectronics&#8217; manufacturing footprint will design and strengthen its complementary ecosystem: in France around digital technologies, in Italy around analog and power technologies, and in Singapore on mature technologies.
STMicroelectronics plans to double the current capacity of the Agrate (Italy) 300mm fab to 4,000 wafers per week (wpw) by 2027, with planned modular expansions increasing capacity to 14,000 wpw, depending on market conditions. The Agrate 200mm fab will refocus on MEMS.
The company plans to boost the capacity of the Crolles (France) 300mm fab to 14,000 wpw by 2027, with planned modular expansions increasing capacity to 20,000 wpw. In addition, the company proposed converting the Crolles 200mm fab to support Electrical Wafer Sorting, a high-volume manufacturing and advanced packaging technology. The focus will be on next-generation leading technologies, including optical sensing and silicon photonics.
Catania will continue to serve as a center of excellence for power and wide-bandgap semiconductor devices. The development of the new Silicon Carbide Campus is progressing as planned, with the production of 200mm wafers set to begin in the fourth quarter of 2025. STMicroelectronics&#8217; resources supporting Catania&#8217;s current 150mm and EWS capabilities will refocus on 200mm silicon carbide and silicon power semiconductor production, including GaN-on-silicon.
Rousset (France) will focus on 200mm manufacturing, with additional volumes reallocated from other sites.
Tours (France) will remain focused on its 200mm silicon production line for select technologies, while other activities, including legacy 150mm manufacturing activities, will be transferred to different STMicroelectronics sites. It will also remain a competence center for GaN, mainly on epitaxy. The Tours site will also host a new activity: panel-level packaging, one of the significant enablers of chiplets, a technology for complex semiconductor applications.
Ang Mo Kio (Singapore), STMicroelectronics&#8217; high-volume fab for mature technologies, will focus on 200mm silicon manufacturing and host its consolidated global legacy 150mm silicon capabilities.
Kirkop (Malta), STMicroelectronics&#8217; high-volume test and packaging fab in Europe, will be upgraded with advanced automated technologies.
As STMicroelectronics reshapes its manufacturing footprint over the next three years, the workforce size and required skill sets will evolve. Advanced manufacturing will shift roles from legacy processes involving repetitive manual tasks to a stronger focus on process control, automation, and design.
Based on current projections, the program will likely see up to 2,800 people leaving the company voluntarily globally, on top of normal attrition. These changes will likely occur mainly in 2026 and 2027.
STMicroelectronics stock plunged 56% in the last 12 months as it struggled to steer a <a target="_blank" href="https://www.benzinga.com/news/management/25/02/43953046/stmicroelectronics-faces-leadership-shakeup-italy-seeks-new-ceo-amid-semiconductor-struggles" rel="noreferrer noopener">slump in demand</a> for automobile and industrial semiconductors.
Reportedly, Italy&#8217;s government is considering replacing&nbsp;STMicroelectronics chief Jean-Marc Chéry after he failed to improve&nbsp;the company&#8217;s prospects. Rome believes the CEO&#8217;s performance is insufficient. Rome and Paris governments hold a combined 27.8% stake in the company.
Price Action: STM stock is up 3.75% at $19.65 in premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44757588/lucid-wins-nikola-bankruptcy-auction-buys-nikola-facilities-for-30-million-to-boost-us-ev-production" target="_blank" rel="noreferrer noopener">Lucid Wins Nikola Bankruptcy Auction, Buys Nikola Facilities for $30 Million To Boost US EV Production</a></li>
</ul>
Photo: Shutterstock

Media

AAPL

TSLA

Tesla And Apple Chip Supplier STMicro Plans Major Restructuring, 2,800 Jobs Set To Exit By 2027

CardiAMP HF II is Evaluating the CardiAMP&#x2122; Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress
Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator
SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=FfIc9Btzt-dDq9riQKpc2FXQMkEak5KABy8xOF5QO01E-uFUwtN75Y5TYhloqVIcvkW8Dzyg2lpUrFAgoixwxQyTEm1mYZYFvhaCMfLqxPk=">BioCardia, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Emory University School of Medicine in Atlanta Georgia is now enrolling patients with ischemic heart failure in the Company's ongoing pivotal Phase III CardiAMP HF II trial. Emory University joins esteemed clinical sites throughout the United States participating in the study.
The CardiAMP HF II Study is evaluating the Company's lead therapeutic product candidate, a system designed for the harvest, processing, and minimally invasive delivery of autologous mononuclear cells to the heart intended to enhance microvascular density and reduce fibrosis. The study is comparing treatment with CardiAMP Therapy to a placebo procedure with all patients on stable guideline directed medical therapy.&nbsp;&nbsp;

BCDA

BioCardia Initiates Enrolling Patients With Ischemic Heart Failure At Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million.

DWTX

Dogwood Therapeutics Regains Nasdaq Compliance

Investment giant BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) stock is trading higher after the company <a href="https://www.benzinga.com/pressreleases/25/04/b44757014/blackrock-reports-first-quarter-2025-earnings" target="_blank" rel="noreferrer noopener">reported first-quarter 2025 results</a>.
Revenue grew&nbsp;12%&nbsp;year over year (Y/Y) to&nbsp;$5.28 billion, missing the consensus of&nbsp;$5.60 billion.&nbsp;
Investment advisory, administration fees and securities lending revenues increased to $4.4 billion from $3.8 billion a year ago, led by higher organic base fees, the impact of market beta on average AUM, and around $285 million of fees related to the GIP Transaction.
Technology services and subscription revenue rose to $436 million from $377 million the prior year, led by continued demand for Aladdin technology offerings and the closing of the acquisition of Preqin Holding Limited in March 2025 (which added around $20 million to the revenues).
BlackRock stated that net inflow stood at&nbsp;$84 billion in the quarter, reflecting 3% annualized organic asset growth, driven by a record first quarter for iShares ETFs, along with private markets and active net inflows.
At the end of the quarter, total AUM was $11.6 trillion, compared to $10.5 trillion in the prior year quarter.
Adjusted operating income rose&nbsp;14% Y/Y to&nbsp;$2.03 billion, with the margin expanding to&nbsp;43.2% from&nbsp;42.2% a year ago.
Adjusted EPS increased&nbsp;15% Y/Y to&nbsp;$11.30,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$11.14.</a>
BlackRock repurchased shares worth&nbsp;$375 million&nbsp;in the quarter and raised&nbsp;the cash dividend per share by 2% to $5.21.
Laurence D. Fink, chairman and CEO, said, &#8221;We delivered 6% organic base fee growth in the first quarter, representing our best start to a year since 2021 and secular strength against a complex market backdrop.&#8221;
Read: <a target="_blank" href="https://www.benzinga.com/25/04/44756747/us-stocks-set-to-open-lower-amid-volatility-ahead-of-major-bank-earnings-fed-is-likely-to-cut-rates-again-on-june-18th-says-expert" rel="noreferrer noopener">US Stocks Likely To Open Lower As Volatility Persists Before Bank Earnings: &#8216;Fed Is Likely To Cut Rates Again On June 18th,&#8217; Says Expert</a>
"Uncertainty and anxiety about the future of markets and the economy are dominating client conversations. We&#8217;ve seen periods like this before when there were large, structural shifts in policy and markets – like the financial crisis, COVID, and surging inflation in 2022,&#8221; Fink added.
Investors can gain exposure to the stock via Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) and Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>).
Price Action: BLK shares are up 1.31% at $870.00 premarket at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44751312/wall-street-on-edge-bank-earnings-inflation-data-consumer-sentiment-set-stage-for-friday-fireworks" target="_blank" rel="noreferrer noopener">Wall Street Braces For High-Stakes Friday With Bank Earnings, Inflation Data, Consumer Sentiment In Focus</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Movers

FDFF

SCHD

BlackRock's Bold Quarter: EPS Tops, $11.6 Trillion AUM, $84 Billion Inflows Power Growth

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">135.73</td>
<td align="right">0.84</td>
<td align="right">0.62</td>
<td>9.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">78.64</td>
<td align="right">0.46</td>
<td align="right">0.58</td>
<td>5.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">90.91</td>
<td align="right">0.41</td>
<td align="right">0.45</td>
<td>6.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">77.33</td>
<td align="right">0.35</td>
<td align="right">0.45</td>
<td>134.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">188.60</td>
<td align="right">0.70</td>
<td align="right">0.37</td>
<td>7.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">123.84</td>
<td align="right">0.35</td>
<td align="right">0.28</td>
<td>4.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">194.87</td>
<td align="right">0.50</td>
<td align="right">0.25</td>
<td>91.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.45</td>
<td align="right">0.10</td>
<td align="right">0.12</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">38.42</td>
<td align="right">0.04</td>
<td align="right">0.10</td>
<td>8.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">45.83</td>
<td align="right">-0.08</td>
<td align="right">-0.18</td>
<td>850.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">75.37</td>
<td align="right">-0.03</td>
<td align="right">-0.04</td>
<td>41.9K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For April 11, 2025

Morgan Stanley analyst Vincent Andrews maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Equal-Weight and lowers the price target from $85 to $80.

Morgan Stanley Maintains Equal-Weight on CF Industries Holdings, Lowers Price Target to $80

Needham analyst Gerald Pascarelli reiterates Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and maintains $215 price target.

Reiteration

Needham Reiterates Buy on Constellation Brands, Maintains $215 Price Target

Morgan Stanley analyst Dara Mohsenian maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Equal-Weight and lowers the price target from $202 to $195.

Morgan Stanley Maintains Equal-Weight on Constellation Brands, Lowers Price Target to $195

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy

Biotech

General

AMGN

Amgen Announced Global Phase 3 DeLLphi-304 Clinical Trial Evaluating IMDELLTRA As Treatment For Patients With Small Cell Lung Cance Met Its Primary Endpoint

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) shares traded higher premarket after the company reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44757876/jpmorganchase-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter&nbsp;FY24 results</a>, but they eventually gave up all the gains and traded in the red.
Reported revenue&nbsp;rose&nbsp;8%&nbsp;year-on-year (Y/Y) to&nbsp;$45.3&nbsp;billion. Net revenue (<a target="_blank" href="https://www.jpmorganchase.com/content/dam/jpmc/jpmorgan-chase-and-co/investor-relations/documents/quarterly-earnings/2025/1st-quarter/d88c408a-bbc9-4b06-b263-373f5b10b145.pdf" rel="noreferrer noopener">managed</a>) was&nbsp;$46.0 billion (+8% Y/Y), beating the&nbsp;consensus of&nbsp;$44.1 billion.
Consumer &amp; Community Banking (CCB) revenue rose&nbsp;4% Y/Y to&nbsp;$18.3&nbsp;billion, and Commercial &amp; Investment Bank (CIB) revenue was&nbsp;$19.7 billion (+12%&nbsp;Y/Y) in the quarter.
Investment Banking revenue was&nbsp;$2.3&nbsp;billion, up&nbsp;2%&nbsp;Y/Y, in the quarter. Investment Banking fees rose&nbsp;12%&nbsp;Y/Y to $2.2 billion, led by higher debt underwriting and advisory fees.
Asset and Wealth Management revenue was&nbsp;$5.73&nbsp;billion (+12% Y/Y), and Corporate revenue stood at&nbsp;$2.30&nbsp;billion (+5% Y/Y) in the quarter.
In AWM,&nbsp;Assets under management stood at&nbsp;$4.1&nbsp;trillion, and client assets stood at&nbsp;$6.0&nbsp;trillion (up&nbsp;15%), driven by higher market levels and continued net inflows.
Net interest income rose 1%&nbsp;year over year to&nbsp;$23.4 billion&nbsp;in the quarter. Net interest income excluding Markets&nbsp;stood at&nbsp;$22.6 billion, down&nbsp;2%&nbsp;year over year due to lower rates and deposit margin compression, along with lower deposit balances in CCB.&nbsp;
Noninterest revenue was&nbsp;$22.6 billion, up&nbsp;17% Y/Y, in the quarter. Noninterest revenue, excluding Markets,&nbsp;increased&nbsp;20%&nbsp;Y/Y to&nbsp;$13.8 billion.
Excluding the $588 million First Republic-related gain, noninterest revenue excluding Markets was up 14%, led by higher asset management fees in AWM and CCB, increased investment banking fees and lower net investment securities losses. Noninterest expense upped 4% Y/Y to&nbsp;$23.6&nbsp;billion&nbsp;in the quarter.
Markets revenue was $9.7 billion, up 21% Y/Y, primarily driven by higher Equity Markets revenue.
Average loans rose&nbsp;1% Y/Y and down 1%&nbsp;quarter-over-quarter (Q/Q); average deposits were down 2% Y/Y and&nbsp;flat&nbsp;Q/Q.
In CCB, Debit and credit card sales volume increased by&nbsp;7%&nbsp;year over year, and active mobile customers were up&nbsp;8% year over year. In CIB, Market revenue rose&nbsp;21%&nbsp;year over year, with Fixed-Income Markets increasing&nbsp;8%&nbsp;year over year and Equity Markets up&nbsp;48% year over year&nbsp;in the quarter.
JPM's provision for credit losses was&nbsp;$3.3 billion (+75% Y/Y), including net charge-offs of&nbsp;$2.3&nbsp;billion and a net reserve build of&nbsp;$973 million.&nbsp;
Net income rose&nbsp;9%&nbsp;Y/Y to&nbsp;$14.6&nbsp;billion in the quarter. EPS of&nbsp;$5.07 exceeded&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;$4.62</a>. The company witnessed a First Republic-related gain of $588 million in Corporate ($0.16 increase in EPS).
The CET1 capital ratio stood at&nbsp;15.4%, and the advanced CET1 capital ratio was&nbsp;15.5%. The bank's capital distributions included a dividend per share of&nbsp;$1.40 and&nbsp;$71 billion&nbsp;of common stock net repurchases.
<a target="_blank" href="https://www.jpmorganchase.com/content/dam/jpmc/jpmorgan-chase-and-co/investor-relations/documents/quarterly-earnings/2024/4th-quarter/9aff0e71-2b8c-4f41-ac93-8da74c263894.pdf" rel="noreferrer noopener">Outlook</a>: JPMorgan expects FY25 net interest income,&nbsp;excluding Markets, of ~$94.5 billion&nbsp;and project card&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">services NCO rate of ~3.60%.</a>
Jamie Dimon, Chairman and CEO, said, "In CCB, the franchise continued to acquire new customers at a robust pace, opening 500,000 net new checking accounts and adding record first-time investors in wealth management. Finally, AWM had healthy AUM net inflows of $90 billion, and investment performance remained strong."
"The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility," he added.
Price Action: JPM shares are down 0.84%&nbsp;at&nbsp;$225.20 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44756747/us-stocks-likely-to-open-lower-as-volatility-persists-before-bank-earnings-fed-is-likely-to-cut-rates-again-on-june-18th-says-expert" target="_blank" rel="noreferrer noopener">US Stock Futures Recover After Early Dip, Poised To Open Higher Amid Volatility: ‘Fed Is Likely To Cut Rates Again On June 18th,' Says Expert</a></li>
</ul>
Image via Shutterstock

Guidance

'Economy Is Facing Considerable Turbulence:' JPMorgan Chase CEO Jamie Dimon Cautions About 'Negatives Of Tariffs And Trade Wars'

WIIM

WKEY

WISeKey International shares are trading higher after the company announced that SEALCOIN demonstrated secure off-grid IoT transactions via LEO satellites and blockchain.

ADTX

Aditxt shares are trading higher after regaining Nasdaq listing requirements compliance.

BMO Capital analyst Andrew Strelzik maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Outperform and lowers the price target from $260 to $215.

BMO Capital Maintains Outperform on Constellation Brands, Lowers Price Target to $215

Orion Properties shares are trading higher after the company provided 2025 year-to-date and Q1 leasing and sales updates, including $19.1 million in vacant asset sales, 425,000 SF leased, and a $243.9 million liquidity buffer.

CORRECTION: Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109

Comments

Babcock & Wilcox

뉴스

파트너 / 기고자

벤징가 글로벌